Lb Pharmaceuticals (LBRX) Other financing activities (2024 - 2026)

Lb Pharmaceuticals' Other financing activities history runs 3 years deep, the most recent figure standing at $29000.0 for Q1 2026.

• On a quarterly basis, Other financing activities changed N/A year-over-year to $29000.0 in Q1 2026; TTM through Mar 2026 was -$327.5 million, a N/A change from a year earlier, with the FY2025 full-year figure at $247000.0, up 973.91% from the prior year.
• Other financing activities improved to $29000.0 in Q1 2026 per LBRX's latest filing, from -$327.5 million in the prior quarter.
• Across five years, Other financing activities topped out at $29000.0 in Q1 2026 and bottomed at -$327.5 million in Q4 2025.
• The 3-year median for Other financing activities is $23000.0 (2024), against an average of -$109.2 million.
• Biggest YoY gain for Other financing activities was 1424026.09% in 2025; the steepest drop was 1424026.09% in 2025.
• Year by year, Other financing activities stood at $23000.0 in 2024, then plunged by 1424026.09% to -$327.5 million in 2025, then jumped by 100.01% to $29000.0 in 2026.
• Per Business Quant, the three latest LBRX Other financing activities figures stand at $29000.0 (Q1 2026), -$327.5 million (Q4 2025), and $23000.0 (Q4 2024).